Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 343 participants.
Also called NCT01917656
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 343 participants
- Sponsor
- Registry
-
NCT01917656
-
- Other papers using this trial's data
- Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA-Ramadan): a randomized trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Algeria, India, Israel, Lebanon, Malaysia, South Africa, United Arab Emirates
- Registry status
- Completed
Technical summary
Registry record NCT01917656. Randomized; no masking; primary purpose treatment. Start 2014-01-09 (actual); primary completion 2014-09-01 (actual). Results posted on 2015-10-07.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes
- Acronym
- LIRA-Ramadan™
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- liraglutide
- Intervention (Drug)
- metformin
- Intervention (Drug)
- sulphonylurea
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct01917656- Content hash
d19279654eafcc9e0c3ad7c8c73f433845325b6f99873c4a156339fbadd43a1a